Rhino-conjunctivitis Quality of Life Questionnaire (RQoL)
In most studies, the study participants were asked to fill a questionnaire before and after the intervention to evaluate the efficacy of treatment. The questions pertained a variation of outcomes including sleep impairment, usual daily activity limitations, emotional functions, symptoms meaningful change and an overall score, which reflected the evaluation of the overall efficacy of the treatment. Four studies with 992 randomized patients provided enough data on an overall score of RQoL that allowed for a quantitative synthesis. The overall score was measured in a 5-point scale in 3 studies11, 14, 15 and in a 7-point scale in 1 study16. In all 4 studies, the respective score ranged from low to high score values indicating excellent to poor effectiveness of treatment respectively. Omalizumab statistically significantly reduced the RQoL by a summary standardized mean difference of -0.45 (95% CI, -0.57, -0.34; p<0.001; I2 = 0%) (Figure 5).